{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.42","upperLimit":"10.81","value":"6.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Progression free survival is defined as time from when the patient is registered on the study until RECIST v1.1 documented disease progression as per the protocol or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Galunisertib: Galunisertib 150mg po BID day 4-17\n\nPaclitaxel: Paclitaxel 175 mg/m2 over 3 hours\n\nCarboplatin: IV day 1 Carboplatin AUC 6\\* over 1 hour (or 5\\* if prior radiation therapy)","id":"OG000","title":"Paclitaxel/Carboplatin + Galunisertib"}],"paramType":"MEDIAN","populationDescription":"Patients who received at least four cycles of study drug.","reportingStatus":"POSTED","timeFrame":"through study completion, an average of 3 years","title":"Median Progression Free Survival (Months)","type":"SECONDARY","unitOfMeasure":"months"}